TENGION
Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported... in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.
TENGION
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2003-01-01
Address:
Audubon, Pennsylvania, United States
Country:
United States
Website Url:
http://www.tengion.com
Total Employee:
51+
Status:
Active
Contact:
3377222436
Total Funding:
297.26 M USD
Technology used in webpage:
Apple Whitelist
Similar Organizations
Exuma Biotech
EXUMA Biotech is a clinical-stage biotechnology company that focuses on discovering and developing CAR-T cell products for solid tumors.
Innovate Biopharmaceuticals
Innovate is a clinical stage biotechnology company developing novel medicines for gastroenterological and orphan disorders.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Mucosis
Mucosis is a clinical stage Dutch biotechnology company developing mucosal vaccines.
Nexus BioPharma
This company is a preclinical stage biotechnology company developing new therapies and intellectual property.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
ORIG3N
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Symvivo Corporation
Symvivo Corporation is a clinical-stage biotechnology company that develops DNA vaccines for genetic and life-threatening diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Celgene
Celgene investment in Post-IPO Equity - Tengion
Oak Investment Partners
Oak Investment Partners investment in Series C - Tengion
L Capital Partners
L Capital Partners investment in Series C - Tengion
HealthCap
HealthCap investment in Series C - Tengion
Quaker BioVentures
Quaker BioVentures investment in Series C - Tengion
Deerfield Partners
Deerfield Partners investment in Series C - Tengion
Safeguard Scientifics
Safeguard Scientifics investment in Series C - Tengion
Bain Capital
Bain Capital investment in Series C - Tengion
J&J Development
J&J Development investment in Series C - Tengion
Bain Capital
Bain Capital investment in Series C - Tengion
